Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...

The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...

Use of the 1.5T Elekta Unity MR-Linac was associated with reduced rates of erectile dysfunction at 6, 12, and 18 months in ...

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients who are newly diagnosed with ...

Pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib requires proactive strategies including supportive medications, dose ...

Panelists discuss how medication adherence significantly impacts chronic myeloid leukemia (CML) treatment outcomes, with research showing even small differences between 90% and 95% adherence to ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma.